Qualigen Therapeutics, Inc.

NASDAQ (USD): Qualigen Therapeutics, Inc. (QLGN)

Last Price

0.166

Today's Change

+0.006 (3.75%)

Day's Change

0.158 - 0.167

Trading Volume

42,190

Profile
QLGN

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Michael S. Poirier Mr. Michael S. Poirier

Full Time Employees:  4 4

IPO Date:  2015-06-23 2015-06-23

CIK:  0001460702 0001460702

ISIN:  US74754R2022 US74754R2022

CUSIP:  74754R103 74754R103

Beta:  0.07 0.07

Last Dividend:  0.00 0.00

Dcf Diff:  0.35 0.35

Dcf:  -0.18 -0.18

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Address

2042 Corte Del Nogal,
Carlsbad, CA 92011, US

760 918 9165

http://www.qualigeninc.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment